Clinical Trial Update: A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating single-agent axitinib as maintenance therapy in first-line metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-01-12